\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe Annual Report on Research and Technological Development Activities of the European Union and Monitoring of Horizon Europe and Horizon 2020 in 2022, has been published here.
A significant part of the report is dedicated to the policy activities of 2022 and focusses on Russia’s war against Ukraine and the consequences for the EU and its R&I landscape. It also includes a monitoring part with data on Horizon Europe, Horizon 2020 and the Euratom programme in 2022.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
